跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 36,122 条关于
“AKT1/3”
全部
36,122
临床试验
17,827
药物
4,685
机构
1,356
资讯
12,254
上个月
Evexta Bio and Roche Ink Clinical Collaboration to Evaluate Rupitasertib Plus Giredestrant in ESR1-Mutated Metastatic Breast Cancer
去年
Truqap plus Abiraterone and ADT Improves rPFS in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
去年
Truqap Plus Abiraterone Shows Promise in PTEN-Deficient Metastatic Prostate Cancer
去年
AstraZeneca Halts Phase 3 Trial of Capivasertib for Metastatic Castration-Resistant Prostate Cancer
去年
Atavistik Bio Doses First Patient in Phase 1 Trial of ATV-1601 for AKT1 E17K-Mutant Solid Tumors
2年前
AstraZeneca's Truqap (capivasertib) Launched in Korea as First AKT Inhibitor for Breast Cancer
上个月
China's NMPA Accepts New Drug Application for Laekna's AKT Inhibitor Afuresertib in HR+/HER2- Breast Cancer
3个月前
Atavistik Bio Secures FDA IND Clearance and Fast Track Designation for ATV-1601 in Hereditary Hemorrhagic Telangiectasia
去年
Truqap Offers New Hope for HR+/HER2- Breast Cancer Treatment in Korea
上个月
Vaderis Therapeutics Secures $152M Series B, Launches Phase 3 HEROIC Trial of Engasertib for HHT
第 1 页,共 1226 页
上一页
下一页